Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the Pneumococcal Vaccine Market’s Growth Rate Evolve Over the Forecast Period to 2034?

The pneumococcal vaccine market has grown steadily in recent years. It is expected to rise from $8.94 billion in 2024 to $9.49 billion in 2025, at a CAGR of 6.2%. The historical growth of this market has been driven by the discovery of Streptococcus pneumoniae, concerns regarding public health, early vaccination initiatives, advancements in healthcare, and changes in vaccine policies.

The pneumococcal vaccine market is anticipated to witness significant growth, reaching $12.12 billion by 2029 with a CAGR of 6.3%. This expansion is driven by evolving pneumococcal strains, ongoing research and development, shifting immunization priorities, broader vaccine accessibility, and an aging population. Key trends expected include multivalent vaccine development, targeted immunization strategies, improved vaccine efficacy, educational campaigns, and a focus on infant vaccination.

What Industry-Specific Factors Are Fueling the Growth of the pneumococcal vaccine Market?

The growing prevalence of pneumococcal infections is expected to accelerate the growth of the pneumococcal vaccine market. Pneumococcal infections, caused by the Streptococcus pneumoniae bacterium, can lead to diseases such as pneumonia, bloodstream infections, and ear infections. Pneumococcal vaccines help the body produce antibodies to combat these infections. For example, in January 2022, the U.S. Centers for Disease Control and Prevention reported that pneumococcal pneumonia leads to around 150,000 hospitalizations annually, accounting for up to 30% of adult community-acquired pneumonia cases. Thus, the rising prevalence of pneumococcal infections is promoting growth in the pneumococcal vaccine market.

Request Your Free Pneumococcal Vaccine Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

Who Are the Influential Players Reshaping the Pneumococcal Vaccine Market Landscape?

Major companies operating in the pneumococcal vaccine market include:

• Pfizer Inc._x000D_

• Johnson & Johnson_x000D_

• Merck & Co. Inc._x000D_

• Sanofi S.A._x000D_

• GlaxoSmithKline plc_x000D_

What New and Evolving Trends Are Having a Lasting Impact on the Pneumococcal Vaccine Market?

Companies in the pneumococcal vaccine market are innovating to boost profitability. For example, in July 2023, Merck & Co Inc., a US-based pharmaceutical company, launched the V116 vaccine, aimed at targeting eight distinct serotypes of Streptococcus pneumoniae that cause adult pneumococcal disease. Compared to other pneumococcal vaccines, V116 has demonstrated superior immunogenicity in adult populations, producing positive immune responses in both vaccine-naïve and previously vaccinated individuals. The U.S. Food and Drug Administration (FDA) has designated V116 as a breakthrough therapy, and it is currently in Phase 3 development.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Which Segments of the Pneumococcal Vaccine Market Hold the Most Potential for Future Development?

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

Which Geographic Locations Are Critical to the Growth of the Pneumococcal Vaccine Market?

North America was the largest region in the pneumococcal vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Defining Aspects of the Pneumococcal Vaccine Market Landscape?

The pneumococcal vaccine refers to a vaccination that offers defense against potentially fatal and severe pneumococcal infections caused by streptococcus pneumoniae bacteria, such as pneumonia, meningitis, and sepsis. It is highly efficient in protecting infants from one of the most common causes of meningitis and other illnesses, such as acute ear infections.

Browse Through More Similar Reports By The Business Research Company:

Medical Waste Management Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/medical-waste-management-global-market-report

Medical Device Cleaning Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/medical-device-cleaning-global-market-report

Medical Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/medical-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: